149 active trials 91 recruiting 7 Phase 3 91 sponsors 14 changes in 30 days
| Early Phase 1 | 3 | |
| Phase 1 | 31 | |
| Phase 1/2 | 28 | |
| Phase 2 | 54 | |
| Phase 2/3 | 2 | |
| Phase 3 | 5 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06647862 | IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic… | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recruiting | 2025-11-25 |
| NCT00843882 | Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic… | National Cancer Institute (NCI) | Active, Not Recruiting | 2026-10-01 |
| NCT05153226 | GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG | DKMS gemeinnützige GmbH | Active, Not Recruiting | 2026-08-27 |
| NCT05883956 | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and… | Otsuka Australia Pharmaceutical Pty Ltd | Active, Not Recruiting | 2025-03-20 |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and… | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Active, Not Recruiting | 2023-09-28 |
| Phase 2/3 | ||||
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With… | M.D. Anderson Cancer Center | Recruiting | 2026-08-11 |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone… | Taiho Oncology, Inc. | Recruiting | 2026-04-30 |
| Phase 2 | ||||
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative… | National Cancer Institute (NCI) | Recruiting | 2026-09-30 |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma… | Mayo Clinic | Recruiting | 2026-09-28 |
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study… | National Cancer Institute (NCI) | Recruiting | 2026-09-25 |
| NCT05554406 | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed… | National Cancer Institute (NCI) | Recruiting | 2026-09-22 |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of… | University of Washington | Recruiting | 2026-09-17 |
| NCT03683433 | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute… | M.D. Anderson Cancer Center | Recruiting | 2026-09-14 |
| NCT06566742 | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of… | M.D. Anderson Cancer Center | Recruiting | 2026-09-11 |
| NCT03383575 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Recruiting | 2026-09-04 |
| NCT07249346 | Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib… | Hannah Choe, MD | Recruiting | 2026-09-02 |
| NCT07582172 | Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as… | City of Hope Medical Center | Recruiting | 2026-08-20 |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With… | Fred Hutchinson Cancer Center | Recruiting | 2026-08-19 |
| NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Theradex | Recruiting | 2026-08-18 |
| NCT02727803 | Personalized NK Cell Therapy in CBT | M.D. Anderson Cancer Center | Recruiting | 2026-07-30 |
| NCT07046078 | Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body… | Fred Hutchinson Cancer Center | Recruiting | 2026-07-20 |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the… | City of Hope Medical Center | Recruiting | 2026-06-29 |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | Masonic Cancer Center, University of Minnesota | Recruiting | 2026-06-25 |
| NCT05365035 | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax… | M.D. Anderson Cancer Center | Recruiting | 2026-06-05 |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in… | University of Florida | Recruiting | 2026-06-04 |
M.D. Anderson Cancer Center (20) · National Cancer Institute (NCI) (10) · Fred Hutchinson Cancer Center (9) · City of Hope Medical Center (8) · Center for International Blood and Marrow Transplant Research (3) · Mayo Clinic (3) · Peking University People's Hospital (3) · Centre Hospitalier Universitaire de Nice (2) · Dana-Farber Cancer Institute (2) · Masonic Cancer Center, University of Minnesota (2)